Unknown

Dataset Information

0

Myeloid cell-specific topoisomerase 1 inhibition using DNA origami mitigates neuroinflammation


ABSTRACT: Targeting myeloid cells, especially microglia, for the treatment of neuroinflammatory diseases such as multiple sclerosis (MS), is underappreciated. Our in silico drug screening reveals topoisomerase 1 (TOP1) inhibitors as promising drug candidates for microglial modulation. We show that TOP1 is highly expressed in neuroinflammatory conditions, and TOP1 inhibition using camptothecin (CPT) and its FDA-approved analog topotecan (TPT) reduces inflammatory responses in microglia/macrophages and ameliorates neuroinflammation in vivo. Transcriptomic analyses of sorted microglia from LPS-challenged mice reveal an altered transcriptional phenotype following TPT treatment. To target myeloid cells, we design a nanosystem using β-glucan-coated DNA origami (MyloGami) loaded with TPT (TopoGami). MyloGami shows enhanced specificity to myeloid cells while preventing the degradation of the DNA origami scaffold. Myeloid-specific TOP1 inhibition using TopoGami significantly suppresses the inflammatory response in microglia and mitigates MS-like disease progression. Our findings suggest that TOP1 inhibition in myeloid cells represents a therapeutic strategy for neuroinflammatory diseases and that the myeloid-specific nanosystems we designed may also benefit the treatment of other diseases with dysfunctional myeloid cells.

SUBMITTER: Dr. Keying Zhu 

PROVIDER: S-SCDT-EMBOR-2021-54499V1P | biostudies-other |

REPOSITORIES: biostudies-other

Similar Datasets

| S-EPMC9253741 | biostudies-literature
| S-EPMC8909553 | biostudies-literature
| S-EPMC8193633 | biostudies-literature
| S-EPMC5161584 | biostudies-literature
| S-EPMC5851876 | biostudies-literature
| S-EPMC6094966 | biostudies-literature
| S-EPMC3852662 | biostudies-literature
| S-EPMC5003508 | biostudies-literature
| S-EPMC7415668 | biostudies-literature
| S-EPMC5739518 | biostudies-literature